Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ironwood Pharma (IRWD) Tops Q2 EPS by 12c, Updates Guidance
August 5, 2021 7:58 AM EDTIronwood Pharma (NASDAQ: IRWD) reported Q2 EPS of $0.34, $0.12 better than the analyst estimate of $0.22. Revenue for the quarter came in at $104.1 million versus the consensus estimate of $93.1 million.
GUIDANCE:
Ironwood Pharma sees FY2021 revenue of $390-410 million, versus the consensus of... More
